Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
After finishing at $8.55 in the prior trading day, Zevra Therapeutics Inc (NASDAQ: ZVRA) closed at $8.53, down -0.23%. In other words, the price has decreased by -$0.23 from its previous closing price. On the day, 0.87 million shares were traded. ZVRA stock price reached its highest trading level at $8.65 during the session, while it also had its lowest trading level at $8.29.
Ratios:
Our goal is to gain a better understanding of ZVRA by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.57 and its Current Ratio is at 8.62. In the meantime, Its Debt-to-Equity ratio is 0.47 whereas as Long-Term Debt/Eq ratio is at 0.47.
Upgrades & Downgrades
In the most recent recommendation for this company, H.C. Wainwright on July 02, 2025, initiated with a Buy rating and assigned the stock a target price of $26. On October 07, 2024, Guggenheim started tracking the stock assigning a Buy rating and target price of $20.Guggenheim initiated its Buy rating on October 07, 2024, with a $20 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 10 ’25 when McFarlane Neil F. sold 19,500 shares for $10.82 per share. The transaction valued at 210,908 led to the insider holds 222,016 shares of the business.
NEIL F MCFARLANE bought 19,500 shares of ZVRA for $210,990 on Oct 10 ’25. On Sep 12 ’25, another insider, FAVORITO TAMARA A, who serves as the Director of the company, bought 3,175 shares for $7.79 each. As a result, the insider paid 24,718 and bolstered with 3,894 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ZVRA now has a Market Capitalization of 480217952 and an Enterprise Value of 343425984. As of this moment, Zevra’s Price-to-Earnings (P/E) ratio for their current fiscal year is 13.52, and their Forward P/E ratio for the next fiscal year is 15.29. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.69 while its Price-to-Book (P/B) ratio in mrq is 3.60. Its current Enterprise Value per Revenue stands at 4.07 whereas that against EBITDA is -14.537.
Stock Price History:
The Beta on a monthly basis for ZVRA is 1.09, which has changed by -0.001168251 over the last 52 weeks, in comparison to a change of 0.13927746 over the same period for the S&P500. Over the past 52 weeks, ZVRA has reached a high of $13.16, while it has fallen to a 52-week low of $6.19. The 50-Day Moving Average of the stock is -9.00%, while the 200-Day Moving Average is calculated to be -6.58%.
Shares Statistics:
The stock has traded on average 1.73M shares per day over the past 3-months and 849160 shares per day over the last 10 days, according to various share statistics. A total of 56.22M shares are outstanding, with a floating share count of 55.84M. Insiders hold about 0.81% of the company’s shares, while institutions hold 71.23% stake in the company. Shares short for ZVRA as of 1764288000 were 6934119 with a Short Ratio of 4.02, compared to 1761868800 on 7103776. Therefore, it implies a Short% of Shares Outstanding of 6934119 and a Short% of Float of 12.3900004.
Earnings Estimates
The firm’s stock currently is rated by 4.0 analysts. The consensus estimate for the next quarter is $0.1, with high estimates of $0.19 and low estimates of $0.03.
Analysts are recommending an EPS of between $1.33 and $1.04 for the fiscal current year, implying an average EPS of $1.16. EPS for the following year is $0.62, with 4.0 analysts recommending between $1.07 and $0.43.
Revenue Estimates
8 analysts predict $28.05M in revenue for. The current quarter. It ranges from a high estimate of $29.9M to a low estimate of $26.6M. As of. The current estimate, Zevra Therapeutics Inc’s year-ago sales were $12.04MFor the next quarter, 8 analysts are estimating revenue of $32.25M. There is a high estimate of $35.95M for the next quarter, whereas the lowest estimate is $29.5M.
A total of 8 analysts have provided revenue estimates for ZVRA’s current fiscal year. The highest revenue estimate was $102.2M, while the lowest revenue estimate was $98.8M, resulting in an average revenue estimate of $100.38M. In the same quarter a year ago, actual revenue was $23.61MBased on 8 analysts’ estimates, the company’s revenue will be $144.08M in the next fiscal year. The high estimate is $168.4M and the low estimate is $131.4M.
